Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Plazomicin in ESRD Patients on Hemodialysis
NCT04699656Phase 1Completed
- Sponsor
- Cipla
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of plazomicin in complicated urinary tract infection (cUTI) and pyelonephritis, sponsored by Cipla. Primary endpoints: Maximum observed plasma drug concentration at 30 days, Time to maximum observed plasma concentration at 30 days and 6 more. Started Jan 2021; status: completed.
02
Drugs
plazomicin
03
Conditions
complicated urinary tract infection (cUTI)pyelonephritis
Beyond the preview
Go deeper on NCT04699656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699656.